VRTX · Vertex Pharmaceuticals Incorporated

Summary

Vertex Pharmaceuticals Incorporated reported consolidated financial results for Q4 and full year 2025, with total revenue of $3.19 billion (up 10% YoY) and $12.0 billion (up 9% YoY), respectively, driven by CF therapies and diversification. The company provided FY 2026 total revenue guidance of $12.95 to $13.1 billion, including $500 million or more from non-CF products.

Key takeaways

• Event Type: Earnings Release (Items: 2.02)